Endocyte, Inc. (NASDAQ:ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that four posters will be presented by Endocytescientists at the 2015 Annual Meeting of the American Association for Cancer Research (AACR) to be held in Philadelphia, April 18-22, 2015.

The presentation materials will be available on Endocyte’s website following presentation at the conference. (Original Source)

Shares of Endocyte closed yesterday at $6.18. ECYT has a 1-year high of $22.75 and a 1-year low of $5.01. The stock’s 50-day moving average is $6.10 and its 200-day moving average is $6.00.

On the ratings front, Endocyte has been the subject of a number of recent research reports. n a report issued on March 3, Wedbush analyst David Nierengarten reiterated a Buy rating on ECYT with a price target of $12, which represents a potential upside of 94.2% from where the stock is currently trading. Separately, on March 2, Cantor Fitzgerald’s Daniel Brims reiterated a Buy rating on the stock and has a price target of $21.

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, David Nierengarten and Daniel Brims have a total average return of 46.1% and -1.6% respectively. Nierengarten has a success rate of 64.0% and is ranked #18 out of 3571 analysts, while Brims has a success rate of 35.7% and is ranked #2888.

Endocyte Inc is a biopharmaceutical company. The Company is engaged in developing targeted therapies for the treatment of cancer and inflammatory diseases.